medicina60巻1号

2023年01月発行

特集 10年前の常識は非常識!?—イマドキ消化器診療にアップデート 疾患

機能性ディスペプシア—これだけでわかる 機能性ディスペプシア診療はどう進化したか？

著者： 山本さゆり¹² 小笠原尚高¹² 春日井邦夫¹²

所属機関： ¹愛知医科大学総合診療科 ²愛知医科大学消化管内科

ページ範囲：P.70 - P.75

　2013年に機能性ディスペプシア（functional dyspepsia：FD）が保険診療名として初めて承認され，2014年に『機能性消化管診療ガイドライン—機能性ディスペプシア』（以下，ガイドライン）第1版が，そして，2021年に第2版が発刊された．本稿ではFD診療のこれまでの流れを踏まえつつ，最新の動向や診療のこつを述べたい．

参考文献

1）Stanghellini V, et al：Gastroduodenal disorders. Gastroenterology 150：1380-1392, 2016

2）Kinoshita Y, Chiba T：Characteristics of Japanese patients with chronic gastritis and comparison with functional dyspepsia defined by ROME III criteria：based on the large-scale survey, FUTURE study. Intern Med 50：2269-2276, 2011

3）Manabe N, et al：Clinical characteristics of Japanese dyspeptic patients；Is the Rome Ⅲ classification applicable? Scand J Gastroenterol 45：567-572, 2010

4）Sugano K, et al：Kyoto global consensus report on Helicobacter pylori gastritis. Gut 64：1353-1367, 2015

5）Schlemper RJ, et al：Peptic ulcer, non-ulcer dyspepsia and irritable bowel syndrome in The Netherlands and Japan. Scand J Gastroenterol Suppl 200：33-41, 1993

6）Okumura T, et al：Prevalence of functional dyspepsia in an outpatient clinic with primary care physicians in Japan. J Gastroenterol 45：187-194, 2010

7）清田啓介：Non-ulcer dyspepsia（NUD）に対する臨床的疫学的研究．日消誌89：1973-1981, 1992

8）Fujikawa Y, et al：Postprandial symptoms felt at the lower part of the epigastrium and a possible association of pancreatic exocrine dysfunction with the pathogenesis of functional dyspepsia. Intern Med 56：1629-1635, 2017

9）Sai JK, et al：Efficacy of camostat mesilate against dyspepsia associated with non-alcoholic mild pancreatic disease. J Gastroenterol 45：335-341, 2010

10）Barbara G, et al：The intestinal microenvironment and functional gastrointestinal disorders. Gastroenterology 150：1305-1318, 2016

11）Simrén M, et al：Intestinal microbiota in functional bowel disorders；A Rome foundation report. Gut 62：159-176. 2013

12）Powell N, et al：The mucosal immune system；Master regulator of bidirectional gut-brain communications. Nat Rev Gastroenterol Hepatol 14：143-159, 2017

13）Lai ST, et al：A quantitative analysis of symptoms of non-ulcer dyspepsia as related to age, pathology, and Helicobacter infection. Scand J Gastroenterol 31：1078-1082, 1996

14）Tahara T, et al：Association of endoscopic appearances with dyspeptic symptoms. J Gastroenterol 43：208-215, 2008

15）Camilleri M, et al：Gastroparesis. Nat Rev Dis Primers 4：41, 2018

16）Pasricha PJ, et al：White Paper AGA：Gastroparesis；Clinical and regulatory insights for clinical trials. Clin Gastroenterol Hepatol 15：1184-1190, 2017

17）Rey E, et al：Prevalence of hidden gastroparesis in the community：the gastroparesis “iceberg”. J Neurogastroenterol Motil 18：34-42, 2012

18）Tack J, et al：The use of pictograms improves symptom evaluation by patients with functional dyspepsia. Aliment Pharmacol Ther 40：523-530, 2014

19）Hongo M, et al：Large-scale randomized clinical study on functional dyspepsia treatment with mosapride or teprenone；Japan Mosapride Mega-Study（JMMS）. J Gastroenterol Hepatol 27：62-68, 2012

20）Spiegel B, et al：Psychometric evaluation of patient-reported outcomes in irritable bowel syndrome randomized controlled trials；A Rome Foundation report. Gastroenterology 137：1944-53.e1-3, 2009

21）Moayyedi P, et al：Pharmacological interventions for non-ulcer dyspepsia. Cochrane Data base Syst Rev 4：CD001960, 2006

22）Pinto-Sanchez MI, et al：Proton pump inhibitors for functional dyspepsia. Cochrane Database Syst Rev 11：Cd011194, 2017

23）Pittayanon R, et al：Prokinetics for functional dyspepsia. Cochrane Database Syst Rev 10：Cd009431, 2018

24）Vijayvargiya P, et al：Effects of promotility agents on gastric emptying and Symptoms；A systematic review and meta-analysis. gastroenterology 156：1650-1660, 2019

25）Yang YJ, et al：Prokinetics for the treatment of functional dyspepsia；Bayesian network meta-analysis. BMC Gastroenterol 17：83, 2017

26）Matsueda K, et al：Clinical trial；Dose-dependent therapeutic efficacy of acotiamide hydrochloride（Z-338）in patients with functional dyspepsia-100 mg t.i.d. is an optimal dosage. Neurogastroenterol Motil 22：618-e173, 2010

27）Xiao G, et al：Efficacy and safety of acotiamide for the treatment of functional dyspepsia；Systematic review and meta-analysis. ScientificWorldJournal 2014：541950, 2014

28）Ford AC, et al：Efficacy of psychotropic drugs in functional dyspepsia；Systematic review and meta-analysis. Gut 66：411-420, 2017

29）秋下雅弘：高齢者の安全な薬物療法ガイドライン 2015．日内会誌105：2398-2402, 2016

30）Suzuki H, et al：Randomized clinical trial：Rikkunshito in the treatment of functional dyspepsia；A multicenter, double-blind, randomized, placebo-controlled study. Neurogastroenterol Motil 26：950-961, 2014

31）Cheong PK, et al：Low-dose imipramine for refractory functional dyspepsia；A randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol 3：837-844, 2018

32）Miwa H, et al：Efficacy of the 5-HT1A agonist tandospirone citrate in improving symptoms of patients with functional dyspepsia；A randomized controlled trial. Am J Gastroenterol 104：2779-2787, 2009

33）Talley NJ, et al：Double-blind placebo-controlled multicentre studies of rebamipide, a gastroprotective drug, in the treatment of functional dyspepsia with or without Helicobacter pylori infection. Aliment Pharmacol Ther 15：1603-1611, 2001

34）Miwa H, et al：Effect of a gastro-protective agent, rebamipide, on symptom improvement in patients with functional dyspepsia；A double-blind placebo-controlled study in Japan. J Gastroenterol Hepatol 21：1826-1831, 2006

35）Jaafar MH, et al：Efficacy of rebamipide in organic and functional dyspepsia；A systematic review and meta-analysis. Dig Dis Sci 63：1250-1260, 2018

36）Matsueda K, et al：A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut 61：821-828, 2012

37）Iwakiri R, e t al：Randomised clinical trial；Rabeprazole improves symptoms in patients with functional dyspepsia in Japan. Aliment Pharmacol Ther 38：729-740, 2013

38）Tominaga K, et al：Rikkunshito simultaneously improves dyspepsia correlated with anxiety in patients with functional dyspepsia；A randomized clinical trial（the DREAM study）. Neurogastroenterol Motil 30：e13319, 2018

39）Moayyedi P, et al：ACG and CAG clinical guideline；Management of dyspepsia. Am J Gastroenterol 112：988-1013, 2017

40）Miwa H：Life style in persons with functional gastrointestinal disorders；Large-scale internet survey of lifestyle in Japan. Neurogastroenterol Motil 24：464-71, e217, 2012

41）Ohlsson B：The role of smoking and alcohol behaviour in management of functional gastrointestinal disorders. Best Pract Res Clin Gastroenterol 31：545-552, 2017

42）Haug TT, et al：Psychotherapy in functional dyspepsia. J Psychosom Res 38：735-744, 1994

43）Orive M, et al：A randomized controlled trial of a 10 week group psychotherapeutic treatment added to standard medical treatment in patients with functional dyspepsia. J Psychosom Res 78：563-568, 2015

44）Calvert EL, et al：Long-term improvement in functional dyspepsia using hypnotherapy. Gastroenterology 123：1778-1785, 2002

45）Meineche-Schmidt V, et al：Impact of functional dyspepsia on quality of life and health care consumption after cessation of antisecretory treatment；A multicentre 3-month follow-up study. Scand J Gastroenterol 34：566-574, 1999

46）Shinozaki S, et al：Adherence to an acotiamide therapeutic regimen improves long-term outcomes in patients with functional dyspepsia. J Gastrointestin Liver Dis 26：345-350, 2017

47）Maconi G, et al：Predictors of long-term outcome of functional dyspepsia and duodenal ulcer after successful Helicobacter pylori eradication；A 7-year follow-up study. Eur J Gastroenterol Hepatol 21：387-393, 2009

48）Ford AC, et al：Effect of dyspepsia on survival；A longitudinal 10-year follow-up study. Am J Gastroenterol 107：912-921, 2012

49）Palsson OS, et al：Development and validation of the Rome Ⅳ Diagnostic Questionnaire for adults. Gastroenterology 150：1481-1491, 2016

50）Eusebi LH, et al：Prevalence of dyspepsia in individuals with gastroesophageal reflux-type symptoms in the community；A systematic review and meta-analysis. Clin Gastroenterol Hepatol 16：39-48.e1, 2018